COGNITIVE TESTS, APOE, BRAIN MRI AND RISKS OF DEMENTIA

描述：该应用程序将CHS作为一个独特的机会， 评估痴呆症风险的主要决定因素和特定类型的 痴呆症的人群样本。 它提出了检验假设， MRI变化，包括梗死样病变（ILL）、高白色物质等级， 高脑沟分级、高脑室分级和局灶性脑萎缩， 与3660名心血管疾病患者中痴呆风险增加相关 健康研究参与者在1992-93年进行了首次MRI， 许多人在1997-98年进行了第二次MRI，现在大约82岁。 该计划旨在评估载脂蛋白E（ApoE） 基因型、炎症指标、亚临床心血管疾病，以及 突发临床疾病（包括中风和心肌梗死）， 心血管风险因素，如高血压和糖尿病，以及 与这些MRI变量的关系。 大部分的数据， 独立变量已经收集。 524黑色 参与者的样本。 所有参与者都将详细了解 神经心理学测试和临床、神经学和精神病学 从近亲和线人那里获得评估信息，以确定 痴呆症的可能诊断的分类基于所有的 来自CHS和神经心理学和临床的可用信息 神经精神评估 申请书建议， 将能够确定MRI结果，特别是与两者相关的 血管病变、脑室分级和海马体积是主要的 痴呆症和痴呆症类型的预测因素，特别是与 ApoE测量、炎症标志物、先前认知功能评分 检查和可能的亚临床血管疾病 我说，这些 关系将足够强大，以允许更好的方法，为早期 确定有痴呆风险的受试者，并可能采取新的方法 到预防。

DESCRIPTION: The application presents the CHS as a unique opportunity to evaluate major determinants of the risk of dementia and specific type of dementia in a population sample. It proposes to test the hypothesis that MRI changes, including infarct-like lesions (ILLs), high white matter grade, high sulci grade, high ventricular grade, and focal brain atrophy are associated with an increased risk of dementia among the 3660 Cardiovascular Health Study participants that had their initial MRI in 1992-93 and, for many, a second MRI in 1997-98 and are now approximately 82 years of age. The plan is to evaluate the relationship between apolipoprotein E (ApoE) genotype, measures of inflammation, subclinical cardiovascular disease, and incident clinical diseas (including stroke and myocardial infarction), cardiovascular risk factors such as hypertension and diabetes, and risk of dementia in relation to these MRI variables. Most of the data for these independent variables have already been collected. There will be 524 Black participants in the sample. All of the participants will have detailed neuropsychological testing and clinical, neurological, and psychiatric evaluation information from next-of-kin and informants in order to determine classification of a possible diagnosis of dementia based on all the available information from the CHS and the neuropsychological and clinical neurological psychiatric evaluation. The application suggests that the CHS will be able to determine whether MRI findings, specifically related to both vascular disease, ventricular grade and hippocampal volume are major predictors of dementia and type of dementia, especially in combination with measurements of ApoE, markers of inflammation, prior scores on cognitive tests and, possibly, subclinical vascular disease. I states that these relationships will be strong enough to allow better methods for early identification of subjects at-risk of dementia and, possibly, new approaches to prevention.